As consumers increasingly seek healthier foods that taste great with minimal ingredients, Novonesis is leveraging biosolutions such as enzymes, cultures, and

The divestment follows the company’s earlier sale of its Feed Enzymes activities to Novonesis in 2025 for €1.5bn, bringing the combined valuation of ANH

Bringing forth a wealth of health properties beyond infant development, human milk oligosaccharides (HMOs) are making their way into diversified nutritional

The partnership brings together State of Green’s public-private platform for promoting Danish green solutions and Novonesis, the world’s leading biosolutions company. The collaboration reflects a growing interest in how biological innovations can enable climate and energy solutions while creating jobs,...

June 2-4, 2026

June 2-4, 2026

June 2-4, 2026

November’s highlights include a spike in global debates over ultra-processed foods (UPFs), US nutrition assistance, Nestlé’s dismissal of added sugar accusations in infant cereal, and our talk with TRAFFIC on the international trade in wild-collected plants. In our November review, Nutrition Insight highlights some of the month’s biggest stories, including breakthrough GLP-1 research and drug development, our discussion with AAK on the impact of supply chains on nutrition innovation, and Novonesis’ latest insights into microbiome-focused healthy longevity innovations. New GLP-1 science and drugs reach “tipping point,” reshaping health and nutrition Emerging science and drug product development are poised to transform

JPMorgan raises Novonesis stock price target to DKK560 on strong growth outlook

Traditionally, HMOs have been studied for their role in beneficially modulating the microbiome, thereby influencing systemic health through immune modulation, gut barrier support, and potential cognitive benefits. However, emerging research reveals that HMOs can be detected systemically in the blood after oral administration, sparking renewed interest in their potential to deliver measurable health outcomes across various life stages. At the same time, Innova Market Insights’ data suggest that global baby and toddler launches with HMOs grew 12% annually from 2019 to 2024, with Europe leading at 42%. Moreover, between 2023 and 2024, 64% featured immune health claims while 2’-Fucosyllactose (2’FL)

Traditionally, HMOs have been studied for their role in beneficially modulating the microbiome, thereby influencing systemic health through immune modulation,

Experts highlight that through technological, medicinal, and nutritional innovations, we are consistently living longer than any generation before. At the same time, the science behind gut health continues to advance as experts unlock the secrets of the gut microbiome. According to Novonesis, the intersection of these two trends presents a plethora of opportunities within the healthy aging space. Innova Market Insights’ data suggests that one in three global consumers is focused on healthy aging as their top physical health priority. From 2019 to 2024, healthy aging product launches grew by 9% annually, with supplements making up 59% of new products.

05.11.2025 Diken Rekabet Kurulu endüstriyel enzim pazarında faaliyet gösteren Novonesis Grubu'na 284,5 mi…

De fem CEO’s fra Mærsk, Novo Nordisk, Novonesis, Carlsberg og Danfoss efterlyser hurtig politisk handling for at styrke EU’s konkurrenceevne.